Another factor that motivates the exploration of EGFR as a possible target in cancer and angiogenesis is associated with the fact that, while this receptor is predominantly not present in standard endothelial cells, selective overexpression commonly occurs by the tumor-related vasculature [92, 93]. This evidence concerns the gene EGFR and neoplasm.